Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — Investor Presentation (February 2025)
35 slides from Collplant Biotechnologies's investor presentation, Feb 12, 2025
Slide 1: CollPlant Corporate Presentation
CollPlant Corporate Presentation Nasdaq : CLGN February 2025
Slide 2: Forward-looking statements disclaimer
The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revis
Slide 3: About CollPlant
About CollPlant A regenerative and aesthetic medicine company Developing innovative technologies and products for tissue regeneration and organ manufacturing The Company's products and candidates are based on rhCollagen that is produced in genetically engineered tobacco plants Strategic agreement wi
Slide 4: Collagen is an Essential Component of the Human Body
Collagen is an Essential Component of the Human Body 25% to 35% of the whole - body protein content The main structural protein in the extracellular matrix found in the body’s organs and various connective tissues* Ideal scaffolding molecule for regenerative medicine *(e.g. cartilage, bones, tendons
Slide 5: Our Technology Platform Produces Human Collagen in Plants at Mass-Scale
N - propeptide C - propeptide COL1 ੑ 1 COL1 ੑ 2 P 4 H ੑ P 4 Hß LH 3 5 Our Technology Platform Produces Human Collagen in Plants at Mass - Scale
Slide 6: rhCollagen: The Ideal Building Block for Regenerative Medicine
Animal Extracted Plant - derived Clear advantages over tissue - extracted (animal - derived) collagen rhCollagen: The Ideal Building Block for Regenerative Medicine Superior homogeneity: allows for creating implants and biological inks with distinct physical properties Improved safety; does not elic
Slide 7: rhCollagen: the Most Characterized Collagen in the Market
rhCollagen: the Most Characterized Collagen in the Market What makes CollPlant rhCollagen so unique? • Genetically and structurally identical to human type 1 Collagen • Non - immunogenic Molecular and physical characterizations are included in the rhCollagen Master File (MAF) currently being assembl
Slide 8: Diverse Product Pipeline
Filler designed to provide soft - tissue regenerative properties Collaborator: AbbVie Status : Clinical phase Dermal/Soft Tissue Fillers Regenerative implants intended for breast augmentation and reconstruction Status: Preclinical phase 3D Bioprinted Breast Implants Regenerative Medical Aesthetics R
Slide 9: How We Are Applying Our rhCollagen: Areas of Focus
How We Are Applying Our rhCollagen: Areas of Focus 9 Status/Partner Commercial Clinical Preclinical Use Product Aesthetic medicine * Dermal/soft tissue fillers Injectable tissue fillers Dermal/soft tissue fillers Photocurable filler Regenerative medicine Breast reconstruction and augmentation Breast
Slide 10: Dermal/Soft Tissue Fillers
10 Dermal/Soft Tissue Fillers
Slide 11: Dermal Fillers: Market Overview
11 Dermal Fillers: Market Overview ~5.3M Hyaluronic Acid procedures in 2023 in the US 1 $6.3B, 10.3% CAGR Global dermal filler market, 2023, CAGR 2023 - 2033 2 $100 - $250/unit Cost per syringe 3 2% 4% 4% 77% 6% 7% Polymethyl methacrylate microspheres Fat Polylactic acid Hyaluronic acid Calcium Hydr
Slide 12: Photocurable Regenerative Dermal Filler
Photocurable Regenerative Dermal Filler 12
Slide 13: Combining the Advantages of Collagen and Hyaluronic Acid
Combining the Advantages of Collagen and Hyaluronic Acid HA Physical properties • Highly viscous: Provides mechanical stability after injection • Convenient injection : 37 - 32 G needle, 10 - 15 N expression force • High lifting capacity • Transparent rhCollagen Biological properties • Promotes cell
Slide 14: Introducing CollPlant State-of-the-Art Photocurable Regenerative Soft Tissue Filler
Introducing CollPlant State - of - the - Art Photocurable Regenerative Soft Tissue Filler Photocurable filler comprised of rhCollagen and hyaluronic acid, injected in a semi - solid phase, hardened in - situ by light illumination Filler Features: 14 Contouring and regeneration may apply to other bod
Slide 15: A Photocurable Dermal Filler would be an all-in-one innovation
High Elasticity High Moldability High Cohesivity High Flexibility A Photocurable Dermal Filler would be an all - in - one innovation: Flexibility compliance with facial expression Moldability precise contour definition Cohesivity maintains the defined shape Elasticity Recovers original shape (aligne
Slide 16: KOL Testimonial: Dr. Jason Bloom
16 KOL Testimonial* Dr. Jason Bloom MD, FACS https://www.bloomfacialplastics.com/ Full video at: https://www.youtube.com/watch?v=D114gdmrdek Use is experimental only at physician’s discretion. CollPlant’s photocurable filler is not yet FDA - approved. BLOOM FACIAL PLASTIC SURGERY • “The first inject
Slide 17: KOL Testimonial: Dr. Sachin Shridharani
17 https:// www.luxurgerynyc.com/dr - shridharani/ Full video at: https://youtu.be/FvdcfO5sQTw Use is experimental only at physician’s discretion. CollPlant’s photocurable filler is not yet FDA - approved. KOL Testimonial Dr. Sachin M. Shridharani, MD, FACS Director - LUXURGERY (New York, NY) • “It
Slide 18: Photocurable Dermal Filler: Injection Areas
Photocurable Dermal Filler: Injection Areas Nasolabial piriform Lateral Zygoma Temple 18 Nasal tip Nasal dorsum Jawline Chin Tissue Layer Injection Areas Intradermal/Subdermal Temple Supraperiosteal Mid face: lateral zygoma Supraperiosteal Mid face: nasolabial piriform Supraperiosteal Chin Subdermal
Slide 19: 3D-bioprinted Regenerative Breast Implants
3D - bioprinted Regenerative Breast Implants 19
Slide 20: Revolutionary Option: The Ability to Regenerate Breast Tissue
Revolutionary Option: The Ability to Regenerate Breast Tissue No regenerative breast implant exists * https://www.fda.gov/medical - devices/breast - implants/medical - device - reports - breast - implant - associated - anaplastic - large - cell - lymphoma 20 Safety issues exist with silicone breast
Slide 21: Breast Implant Market Overview
21 Breast Implant Market Overview 1. 2. 3. www.imarcgroup.com/breast - implant - market www.webmd.com/beauty/cosmetic - procedures - breast - augmentation# 1 https://finance.yahoo.com/news/global - breast - implants - market - report - 133700143.html 60% Breast Augmentation 21% Breast Lift Reconstru
Slide 22: The Challenges in Development of a Regenerative Breast Implant
The Challenges in Development of a Regenerative Breast Implant Patient • Natural feeling (dynamic conditions) • Affordable cost • Patient - to - patient variability (e.g., age, fat tissue) Plastic Surgeon • Implant handling • Implant administration o Incision size o Simple procedure Tissue • Soft ti
Slide 23: CollPlant's 3D Bioprinted Breast Implants
CollPlant’s 3D Bioprinted Breast Implants 3D printed Breast scaffold: rhColl - MA based formulation Printed implant Implantation and vascularization Implant replacement by newly formed tissue Implant design using M&S* methodologies 23 * M&S – Modeling & Simulation
Slide 24: New Approach for Implant Design
New Approach for Implant Design ݑ ݕ /ℎ ܪ ݅ ݃ ℎ ܮ ݓ Material 3D Model 24 *Finite Element Analysis FEA* Simulation
Slide 25: Simulations of Real-Life Scenarios
Simulations of Real - Life Scenarios Breast Simulations Human Body Model Simulations 25
Slide 26: 3D Bioprinting of a Regenerative Breast Implant with rhCollagen BioInk
3D Bioprinting of a Regenerative Breast Implant with rhCollagen BioInk 26
Slide 27: Controlling the Mechanical Properties
Controlling the Mechanical Properties Compression Force [N] Strain [%] Commercial Silicone implants CollPlant’s regenerative breast implants 10 20 30 40 50 60 27
Slide 28: Simple Implantation Procedure
Simple Implantation Procedure 28
Slide 29: Estimated Tissue Regeneration and Implant Re-Modeling
Estimated Tissue Regeneration and Implant Re - Modeling 0 12 Months Volume 3 6 9 1 2 Tissue Regeneration Implant Re - modeling External volume retention 29
Slide 30: Large Animal Study Results
Explant Mechanical Test Fat tissue Penetration MRI 30 Blood flow U/S Blood vessels MRI Tissue growth MRI 1M 2M Large Animal Study Results
Slide 31: rhCollagen-based Bioink Platform for Biofabrication
rhCollagen - based Bioink Platform for Biofabrication Animal - free: excellent safety profile, non immunogenic Optimal rheology at room temperature Cytocompatible, Biofunctional Compatible with major printing technologies Mass production - consistency robustness High homogeneity reproducibility 31
Slide 32: Seasoned Management Team with Engineering, Pharmaceutical, Device and Life Sciences Experience
Seasoned Management Team with Engineering, Pharmaceutical, Device and Life Sciences Experience Yehiel Tal CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries Eran Rotem Deputy CEO & CFO Tefron, CFO (NYSE,TASE) Healthcare Tech., CFO (NASDAQ) & Gamida, E&Y Elana Gazal, PhD VP R&D Neur
Slide 33: Our Goals through 2025
Our Goals through 2025 Dermal fillers: Continue to advance development Commercial - sized breast implants: Expand studies in large animals to generate additional safety and efficacy data in support of commercialization ESG: Continue operations in line with Climate Action, energy efficiency, sustaina
Slide 34: Investment Summary
Investment Summary Pioneering Proprietary, Plant - Based Technology Platform The only commercially viable technology that can produce truly human collagen at mass scale and without reliance on animal tissue Addressing Multi - billion - dollar markets Innovative rhCollagen technology initially focuse
Slide 35: A } Fa
BZ 4 A } Fa (allan
CollPlant Biotechnologies — Investor Presentation (February 2025) on 6ix